All in on novel target GSK-3β, Actuate Therapeutics raises $21M+ to bankroll ambitious PhI/II Endpoints News By John Harbison|2019-05-18T15:40:40-08:00May 17, 2019|Tech Coast Angels Portfolio Companies in the Press|Comments Off on All in on novel target GSK-3β, Actuate Therapeutics raises $21M+ to bankroll ambitious PhI/II Share This Story, Choose Your Platform! FacebookTwitterRedditLinkedInWhatsAppTumblrPinterestVkXingEmail About the Author: John Harbison Related Posts
